-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
InMed Pharmaceuticals Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2019 to Q4 2023.
- InMed Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2023 was -$1.48M, a 29.6% increase year-over-year.
- InMed Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2023 was -$6.35M, a 62.5% increase year-over-year.
- InMed Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$7.95M, a 57.3% increase from 2022.
- InMed Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$18.6M, a 82.3% decline from 2021.
- InMed Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$10.2M, a 14.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)